<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23093" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Primary Hyperaldosteronism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cobb</surname>
            <given-names>Alexander</given-names>
          </name>
          <aff>Michigan State/McLaren Greater Lansing</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexander Cobb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>12</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23093.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Primary hyperaldosteronism (PA) is an underdiagnosed cause of hypertension. The classic presentation of PA includes hypertension and hypokalemia. However, in reality, most patients will present without hypokalemia. The two primary causes are aldosterone-producing adenomas and bilateral adrenal hyperplasia of the zona glomerulosa. Familial cases have been found and are classified into Type I, Type II, and Type III familial hyperaldosteronism. Diagnosis can initially be confirmed with the elevated morning aldosterone to plasma renin activity ratio. If the ratio is higher than 20 to 1, then the excess aldosterone points to the adrenal gland as the primary source. The preferred treatment is adrenalectomy in those with unilateral disease. Those who are poor surgical candidates or have bilateral adrenal hyperplasia can be treated medically with mineralocorticoid antagonists as well as antihypertensive agents for further blood pressure control. This activity reviews the evaluation and management of primary hyperaldosteronism and highlights the role of the interprofessional team in identifying and treating this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the common presentation of primary hyperaldosteronism.</p></list-item><list-item><p>Review the evaluation of primary hyperaldosteronism.</p></list-item><list-item><p>Summarize the treatment options for primary hyperaldosteronism.</p></list-item><list-item><p>Identify interprofessional strategies regarding the evaluation and management of primary hyperaldosteronism to ensure up-to-date best practices are employed, thereby improving patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23093&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23093">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23093.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary hyperaldosteronism (PA) is an underdiagnosed cause of hypertension. The presentation is classically known to occur in a patient with hypertension and hypokalemia. However, in reality,&#x000a0;most patients will present without hypokalemia. The two primary causes are aldosterone-producing adenomas and bilateral adrenal hyperplasia of the zona glomerulosa. Some familial causes have been found and are classified into Type I, Type II, and Type III familial hyperaldosteronism. Diagnosis can initially be confirmed with the elevated morning aldosterone to plasma renin activity ratio. If the ratio is higher than 20 to 1, then the excess aldosterone points to the adrenal gland as the primary source.&#x000a0;The preferred treatment is adrenalectomy in those with unilateral disease. Those who are poor surgical candidates or have bilateral adrenal hyperplasia can be treated medically with mineralocorticoid antagonists as well as antihypertensive agents for further blood pressure control.</p>
      </sec>
      <sec id="article-23093.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The most prevalent cause of primary hyperaldosteronism is aldosterone-producing adenomas. Other causes include aldosterone-producing adrenal carcinoma, ectopic aldosterone secretion from the kidneys or ovaries, and bilateral zona glomerulosa hyperplasia. There are familial causes as well. Type I is glucocorticoid-remediable hyperaldosteronism&#x000a0;that&#x000a0;results from the formation of a chimeric gene containing the regulator portion of 11B-hydroxylase (usually regulated by ACTH) and the synthetic region of aldosterone synthase; as a&#x000a0;result, ACTH stimulates aldosterone synthase and hence aldosterone production. Type II causes are unclear; it correlates to a gene on 7p22 (band 11q13), and histologic findings are consistent with hyperplasia or adenomas.<xref ref-type="bibr" rid="article-23093.r1">[1]</xref> Type III results from a mutation in KCNJF, which is a potassium channel coding gene. This mutation causes increased calcium ion availability in the glomerulosa cells leading to increased aldosterone synthesis.<xref ref-type="bibr" rid="article-23093.r2">[2]</xref><xref ref-type="bibr" rid="article-23093.r3">[3]</xref></p>
      </sec>
      <sec id="article-23093.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Primary hyperaldosteronism occurs worldwide,&#x000a0;and no evidence suggests that there are more cases of primary hyperaldosteronism in certain areas of the world.&#x000a0;Aldosterone-producing adenomas occur more frequently in women than in men. Reports are that there may be a higher prevalence in African Americans or persons of African origin; this is demonstrated more in the idiopathic adrenal hyperplasia variant of the disease.<xref ref-type="bibr" rid="article-23093.r4">[4]</xref><xref ref-type="bibr" rid="article-23093.r5">[5]</xref></p>
      </sec>
      <sec id="article-23093.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A patient with suspected primary hyperaldosteronism will present with uncontrolled hypertension and will typically&#x000a0;be young.&#x000a0;These patients will require up to three antihypertensive medications, including a diuretic, to maintain suboptimal blood pressure control. They can also have a family history of early-onset hypertension or cerebral vascular disease at a younger&#x000a0;age. Patients may have severe muscle weakness, palpitations, fatigue, or muscle cramps due to symptoms related to hypokalemia. Polydipsia and polyuria are present due to nephrogenic diabetes insipidus, likely secondary to hypokalemia.&#x000a0;</p>
        <p>Hypokalemia has been considered one of the hallmark signs in the diagnosis of primary aldosteronism; however, estimates are now that less than 37 percent of patients who have primary hyperaldosteronism will present with&#x000a0;hypokalemia.<xref ref-type="bibr" rid="article-23093.r5">[5]</xref> Patients who have adequate sodium intake will often be more hypokalemic. Increasing sodium intake will allow more sodium delivery to the cortical collecting tubules promoting further excretion of potassium in the setting of excess aldosterone.<xref ref-type="bibr" rid="article-23093.r5">[5]</xref> Even though patients typically do not present with hypokalemia, the diagnosis should be considered in a patient with drug-resistant hypertension and hypokalemia in a patient starting a low dose of diuretic.</p>
        <p>There are no physical exam characteristics that will lead to a diagnosis of primary hyperaldosteronism. However, due to excessive hypertension and stress on the heart, left ventricular hypertrophy can occur, leading to an S4 heart sound secondary to blood trying to enter a noncompliant stiff ventricle during atrial contraction. Other findings related to longstanding hypertension can arise throughout the body affecting the heart (heart failure), kidneys (proteinuria), eyes (hypertensive retinal changes), vasculature (carotid bruits/stroke symptoms), muscle weakness, and mental status changes secondary to hypertensive encephalopathy.&#x000a0;</p>
      </sec>
      <sec id="article-23093.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The Endocrine Society recommends screening for specific patient presentations. Patients with hypertension on triple-drug therapy and diuretic-induced hypokalemia; patients with hypertension and adrenal incidentaloma; hypertension with a family history of the early-onset cerebral vascular accident; or patients with hypertension and first-degree relatives with confirmed primary hyperaldosteronism.<xref ref-type="bibr" rid="article-23093.r6">[6]</xref></p>
        <p>Suspect primary aldosteronism when a patient presents with hypertension at an early age with hypokalemia and poorly controlled blood pressure despite medical therapy. The next step is to obtain a morning plasma aldosterone and renin activity. If the ratio of morning aldosterone to plasma renin activity is higher than 20 to 1, then the excess aldosterone can be attributed to the adrenal gland as the primary source. Next, any of the four confirmatory tests may follow: 1) oral sodium loading 2) saline infusion 3) fludrocortisone suppression 4) captopril challenge, which should suppress aldosterone; however, in a patient with primary aldosteronism, there will be a lack of aldosterone suppression. Once primary aldosteronism is confirmed, all suspected patients are recommended to undergo an adrenal computed tomography scan as the initial study and to exclude possible adrenocortical carcinoma. It is then recommended for the patient to have an adrenal venous sampling.<xref ref-type="bibr" rid="article-23093.r7">[7]</xref></p>
        <p>The best diagnostic test involves the measurement of&#x000a0;cortisol and aldosterone in bilateral adrenal venous effluent and a peripheral vein before and during an ACTH infusion. Cortisol will be used to evaluate the catheter placement in the adrenal veins, as levels from the two sides should be similar. When an adenoma is present, the aldosterone-to-cortisol ratio on one side is usually at least five times greater than the other, indicating&#x000a0;suppression. Bilateral hyperplasia tends to produce similar values on each side. If the study points towards a unilateral&#x000a0;adenoma,&#x000a0;then laparoscopic adrenalectomy is the preferred treatment. If the patient declines surgery or is not a surgical candidate, medical therapy is the recommended route. If the study points towards a bilateral cause, then medical treatment with a mineralocorticoid antagonist is warranted.<xref ref-type="bibr" rid="article-23093.r8">[8]</xref></p>
      </sec>
      <sec id="article-23093.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for primary hyperaldosteronism includes laparoscopic resection for adenomas. This procedure will usually resolve hypokalemia,&#x000a0;but hypertension can persist in up to 65% of patients postadrenalectomy. Surgery is the preferred treatment for patients with unilateral aldosterone-producing adenoma. After unilateral adrenalectomy, almost all patients have the resolution of hypokalemia and moderate improvement in blood pressure control.<xref ref-type="bibr" rid="article-23093.r9">[9]</xref> In those who are unable to undergo surgery or have bilateral adrenal hyperplasia,&#x000a0;mineralocorticoid antagonists such as spironolactone or eplerenone are an option. In a randomized study, the antihypertensive effects between spironolactone and eplerenone in patients with primary hyperaldosteronism were studied, showing that spironolactone was more effective than eplerenone in controlling blood pressure.<xref ref-type="bibr" rid="article-23093.r10">[10]</xref> Amiloride, a sodium channel blocker, may be helpful in the treatment, and other antihypertensive agents can be continued as needed to optimize blood pressure control. Spironolactone is considered the first-line agent for patients who cannot undergo surgical resection.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-23093.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In patients with refractory hypertension, some other differentials to include are renal artery stenosis, secondary aldosteronism, pheochromocytoma (spontaneous and drug-mediated),<xref ref-type="bibr" rid="article-23093.r11">[11]</xref> deoxycorticosterone secreting tumors, renin-secreting tumor from the juxtaglomerular apparatus, and renovascular ischemia.<xref ref-type="bibr" rid="article-23093.r12">[12]</xref> Excessive licorice intake can lead to the impairment of the conversion of cortisol to cortisone in the kidneys; this is because the&#x000a0;glycyrrhizinic&#x000a0;acid portion of the&#x000a0;licorice&#x000a0;inhibits 11-beta-hydroxysteroid dehydrogenase. Excess cortisol will then bind to mineralocorticoid receptors acting as a mineralocorticoid.<xref ref-type="bibr" rid="article-23093.r13">[13]</xref></p>
        <p>Other genetic diseases presenting similarly to primary hyperaldosteronism include but are not limited to:</p>
        <p>Chr&#x000e9;tien syndrome is a rare syndrome that is caused by excess secretion of POMC from pituitary adenoma leading to adrenocortical hypertension.<xref ref-type="bibr" rid="article-23093.r14">[14]</xref></p>
        <p>Gitelman syndrome, which is a loss of function of the sodium chloride cotransporter in the renal tubules, leading to salt wasting and secondary hyperaldosteronism.<xref ref-type="bibr" rid="article-23093.r15">[15]</xref></p>
        <p>Liddle syndrome&#x000a0;is a&#x000a0;pseudohyperaldosteronism&#x000a0;which is a rare autosomal dominant disorder causing hyperactive renal epithelial sodium channels with increased sodium reabsorption in the distal tubules. In this syndrome, levels of renin and aldosterone are low.<xref ref-type="bibr" rid="article-23093.r16">[16]</xref></p>
      </sec>
      <sec id="article-23093.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Studies show that morbidity and mortality of those with primary hyperaldosteronism are directly related to chronic elevated hypertension leading to increased risk of cardiovascular disease, including CAD, stroke, and congestive heart failure secondary to left ventricular hypertrophy.<xref ref-type="bibr" rid="article-23093.r17">[17]</xref><xref ref-type="bibr" rid="article-23093.r18">[18]</xref> Other studies point to the increased risk of cardiac arrhythmias secondary to persistent hypokalemia in those with primary hyperaldosteronism.[14] Research has shown in individual studies that surgical correction by adrenalectomy leads to a better prognosis by a significant reduction in hypertension and hypokalemia when compared to those with medical therapy.<xref ref-type="bibr" rid="article-23093.r19">[19]</xref></p>
      </sec>
      <sec id="article-23093.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Cardiovascular risk is associated with patients who have primary aldosteronism because these patients will have greater mass measurements of the left ventricle as well as decreased left ventricular function when compared to patients with other types of hypertension.<xref ref-type="bibr" rid="article-23093.r20">[20]</xref><xref ref-type="bibr" rid="article-23093.r21">[21]</xref> Other cardiovascular risks include stroke, atrial fibrillation, and myocardial infarction. There was a prospective study done comparing 54 patients with primary hyperaldosteronism who had treatment with either spironolactone, a mineralocorticoid receptor antagonist, or surgical resection of an adrenal adenoma. The control group was patients with primary hypertension matched for age, gender, BMI, and duration of hypertension. The study found that before treatment, patients with primary hyperaldosteronism had a greater prevalence of cardiovascular events than those with primary hypertension. After treatment of the mineralocorticoid excess, whether it be by surgical resection of adenomas or by spironolactone, there was no longer an elevated cardiovascular risk for those with primary hyperaldosteronism. The patients received follow-ups for roughly seven years, and there was no significant difference between each group when it came to&#x000a0;reaching&#x000a0;the primary outcome of myocardial infarction, revascularization procedure, sustained arrhythmia, or stroke.<xref ref-type="bibr" rid="article-23093.r22">[22]</xref></p>
        <p>Metabolic syndrome&#x000a0;is more common in those with primary hyperaldosteronism as compared to controls with similar blood pressure, sex, age, and BMI.<xref ref-type="bibr" rid="article-23093.r23">[23]</xref></p>
        <p>Increased aldosterone blood levels&#x000a0;lead&#x000a0;to increasing GFR and renal perfusion pressure. These patients will also have increased urinary albumin excretion. A study of a series of 50 patients with primary aldosteronism treated with either adrenalectomy or spironolactone was compared to those with primary hypertension on antihypertensive therapy. The results showed that at baseline, patients with primary aldosteronism had higher GFRs and albumin excretion than patients with primary hypertension. However, after a six-month follow-up of the treated primary aldosteronism patients, it was found that albuminuria was significantly decreased in addition to the reduction in the GFR when compared to the primary hypertension group.<xref ref-type="bibr" rid="article-23093.r24">[24]</xref> This research shows that with surgical resection or medical therapy in those with primary hyperaldosteronism, an underlying renal insufficiency could be present due to reversing the hyperfiltration state.&#x000a0;&#x000a0;</p>
        <p>Prior stroke was found to be significantly higher in patients with primary hyperaldosteronism (12.9%) than those with primary hypertension (3.4%) in a retrospective study comparing a total of 124 patients with primary hyperaldosteronism and 465 patients with primary hypertension. The two groups had similar ages, genders, and mean blood pressure of 175/107.<xref ref-type="bibr" rid="article-23093.r25">[25]</xref></p>
      </sec>
      <sec id="article-23093.s11" sec-type="Consultations">
        <title>Consultations</title>
        <p>Nephrology</p>
        <p>Endocrinology</p>
        <p>General surgery</p>
        <p>Interventional radiology</p>
      </sec>
      <sec id="article-23093.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about the common symptoms of primary hyperaldosteronism and be aware of the common family history findings to report to their physicians. Patients should be mindful of bringing up any early family history of hypertension or stroke in an immediate family member. When diagnosed with hyperaldosteronism, patients should understand the importance of compliance with medical therapy as this is the only treatment besides surgical intervention. Patients diagnosed with essential hypertension at a young age that have been refractory to treatment on multiple medications should mention to the primary care physicians of their compliance and provide a record of blood pressure readings as this will help their physician evaluate further causes of hypertension.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-23093.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In patients with suspected primary hyperaldosteronism, it is critical to maintain interprofessional communication between the primary care physician, endocrinologist, nurse practitioner,&#x000a0;and laboratory team. The workup of suspected primary hyperaldosteronism involves an initial blood test of aldosterone to plasma renin activity, and this needs to be drawn early in the morning, preferably before 8 am. Discussion between the healthcare provider&#x000a0;and lab team should take place if working in the hospital or conversation with the patient if working up is outpatient. Confirmatory tests, including oral sodium loading or saline infusion, require timely blood draws by lab staff and careful instruction to the patient for sodium loading to allow for accurate results. Once diagnosed, especially by an endocrinologist, it is important to thoroughly document the steps of the workup and goals of treatment as this will help the interprofessional communication with the primary care physician, nurse practitioner, or surgeon if the patient is a surgical candidate for adrenalectomy. A thorough explanation of the treatment options should be given to the patient to allow them to be a part of the medical team.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-23093.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23093&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23093">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/primary-hyperaldosteronism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23093">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23093/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23093">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23093.s15">
        <title>References</title>
        <ref id="article-23093.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funder</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The genetic basis of primary aldosteronism.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-4</page-range>
            <pub-id pub-id-type="pmid">22359160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholl</surname>
                <given-names>UI</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rklund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nelson-Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Men</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lolis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wisgerhof</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hellman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>&#x000c5;kerstr&#x000f6;m</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Carling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.</article-title>
            <source>Science</source>
            <year>2011</year>
            <month>Feb</month>
            <day>11</day>
            <volume>331</volume>
            <issue>6018</issue>
            <fpage>768</fpage>
            <page-range>768-72</page-range>
            <pub-id pub-id-type="pmid">21311022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>S&#x000f6;derkvist</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gimm</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Genetics of primary hyperaldosteronism.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>R437</fpage>
            <page-range>R437-54</page-range>
            <pub-id pub-id-type="pmid">27485459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000e4;yser</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Deinum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Grauw</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Schalk</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Bor</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Schermer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Biermans</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of primary aldosteronism in primary care: a cross-sectional study.</article-title>
            <source>Br J Gen Pract</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>667</issue>
            <fpage>e114</fpage>
            <page-range>e114-e122</page-range>
            <pub-id pub-id-type="pmid">29335324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulatero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Fardella</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Mosso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Veglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>1045</fpage>
            <page-range>1045-50</page-range>
            <pub-id pub-id-type="pmid">15001583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>179</volume>
            <issue>1</issue>
            <fpage>R19</fpage>
            <page-range>R19-R29</page-range>
            <pub-id pub-id-type="pmid">29674485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Primary aldosteronism: diagnostic and treatment strategies.</article-title>
            <source>Nat Clin Pract Nephrol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>198</fpage>
            <page-range>198-208; quiz, 1 p following 230</page-range>
            <pub-id pub-id-type="pmid">16932426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism.</article-title>
            <source>Hypertension</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-60</page-range>
            <pub-id pub-id-type="pmid">24218436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milsom</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Espiner</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Gwynne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>The blood pressure response to unilateral adrenalectomy in primary aldosteronism.</article-title>
            <source>Q J Med</source>
            <year>1986</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>236</issue>
            <fpage>1141</fpage>
            <page-range>1141-51</page-range>
            <pub-id pub-id-type="pmid">3659251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parthasarathy</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>M&#x000e9;nard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Connell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.</article-title>
            <source>J Hypertens</source>
            <year>2011</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>980</fpage>
            <page-range>980-90</page-range>
            <pub-id pub-id-type="pmid">21451421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosseinnezhad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Adhikari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-induced pheochromocytoma crisis.</article-title>
            <source>Endocr Pract</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>e51</fpage>
            <page-range>e51-4</page-range>
            <pub-id pub-id-type="pmid">21324811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rimoldi</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Scherrer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Secondary arterial hypertension: when, who, and how to screen?</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>May</month>
            <day>14</day>
            <volume>35</volume>
            <issue>19</issue>
            <fpage>1245</fpage>
            <page-range>1245-54</page-range>
            <pub-id pub-id-type="pmid">24366917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabbadin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Armanini</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Syndromes that Mimic an Excess of Mineralocorticoids.</article-title>
            <source>High Blood Press Cardiovasc Prev</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-5</page-range>
            <pub-id pub-id-type="pmid">27251484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schiffrin</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Chr&#x000e9;tien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seidah</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Lis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutkowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cantin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Genest</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Response of human aldosteronoma cells in culture to the N-terminal glycopeptide of pro-opiomelanocortin and gamma 3-MSH.</article-title>
            <source>Horm Metab Res</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>181</fpage>
            <page-range>181-4</page-range>
            <pub-id pub-id-type="pmid">6862354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujimura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nozu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Minamikawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horinouchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sakakibara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyako</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nozu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morisada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nagase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ninchoji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iijima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Genetic Characteristics in Patients With Gitelman Syndrome.</article-title>
            <source>Kidney Int Rep</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-125</page-range>
            <pub-id pub-id-type="pmid">30596175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CX</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>KQ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XL</given-names>
              </name>
            </person-group>
            <article-title>Liddle syndrome misdiagnosed as primary aldosteronism resulting from a novel frameshift mutation of SCNN1B.</article-title>
            <source>Endocr Connect</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1528</fpage>
            <page-range>1528-1534</page-range>
            <pub-id pub-id-type="pmid">30496127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galetta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Franzoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bardini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taurino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghiadoni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bernini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salvetti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism.</article-title>
            <source>J Hypertens</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>2399</fpage>
            <page-range>2399-405</page-range>
            <pub-id pub-id-type="pmid">19008719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inagaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Itoh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Umakoshi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsuiki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ichijo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katabami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shibayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawashima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kamemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Otsuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Izawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoneda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yanase</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tabara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <collab>Nagahama Study</collab>
              <collab>JPAS Study Group</collab>
            </person-group>
            <article-title>Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>530</fpage>
            <page-range>530-537</page-range>
            <pub-id pub-id-type="pmid">29358460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyake</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takayanagi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sasano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ueshiba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katabami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katsumata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tajima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanase</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study.</article-title>
            <source>Endocr J</source>
            <year>2014</year>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-40</page-range>
            <pub-id pub-id-type="pmid">24077222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshihara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nishikimi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshitomi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakasone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Omae</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension.</article-title>
            <source>Am J Hypertens</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>523</fpage>
            <page-range>523-8</page-range>
            <pub-id pub-id-type="pmid">8783775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stowasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marwick</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>90</volume>
            <issue>9</issue>
            <fpage>5070</fpage>
            <page-range>5070-6</page-range>
            <pub-id pub-id-type="pmid">15941863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colussi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nadalini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chiuch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baroselli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lapenna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sechi</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular outcomes in patients with primary aldosteronism after treatment.</article-title>
            <source>Arch Intern Med</source>
            <year>2008</year>
            <month>Jan</month>
            <day>14</day>
            <volume>168</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-5</page-range>
            <pub-id pub-id-type="pmid">18195199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanslik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wallaschofski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riester</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allolio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quack</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rump</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Willenberg</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Beuschlein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Quinkler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hannemann</surname>
                <given-names>A</given-names>
              </name>
              <collab>participants of the German Conn's Registry</collab>
            </person-group>
            <article-title>Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>173</volume>
            <issue>5</issue>
            <fpage>665</fpage>
            <page-range>665-75</page-range>
            <pub-id pub-id-type="pmid">26311088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sechi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Novello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lapenna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baroselli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nadalini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colussi</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Catena</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Long-term renal outcomes in patients with primary aldosteronism.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Jun</month>
            <day>14</day>
            <volume>295</volume>
            <issue>22</issue>
            <fpage>2638</fpage>
            <page-range>2638-45</page-range>
            <pub-id pub-id-type="pmid">16772627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23093.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milliez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Girerd</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Blacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Safar</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mourad</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2005</year>
            <month>Apr</month>
            <day>19</day>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1243</fpage>
            <page-range>1243-8</page-range>
            <pub-id pub-id-type="pmid">15837256</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
